Longitudinal analysis of serum microRNAs as predictors of cirrhosis regression during treatment of hepatitis B virus infection.
antiviral therapy
biomarker
hepatitis B virus
inflammation
tenofovir
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
22
03
2019
revised:
27
01
2020
accepted:
08
04
2020
pubmed:
18
4
2020
medline:
22
6
2021
entrez:
18
4
2020
Statut:
ppublish
Résumé
Most patients with cirrhosis induced by chronic HBV infection experience fibrosis regression after long-term antiviral treatment, while some remain cirrhotic. Fibrosis regression is associated with lower odds of developing hepatic decompensation and hepatocellular carcinoma, but mechanisms impacting differential fibrosis regression between individuals are unclear. We asked whether soluble molecules, including serum microRNAs, could serve as biomarkers of fibrosis regression. We analysed cryopreserved sera from clinical trials in which cirrhotic HBV-infected patients (baseline Ishak fibrosis score of 5-6) received 240 weeks of nucleotide analogue treatment. Liver biopsies at week 240 in these trials showed 71/96 patients (74%) had fibrosis regression (Ishak ≤ 4) while 25/96 (26%) remained cirrhotic (Ishak 5-6). We quantified inflammatory markers (CXCL10, soluble CD163) and miRNAs (n = 179) from serum at baseline, week 48 and week 240 of treatment in a sub-cohort of patients with (n = 14) or without (n = 14) fibrosis regression. CXCL10, sCD163 and miRNAs previously associated with HBV replication and inflammation decreased during treatment but did not differ based on fibrosis regression. Two miRNAs (miR-421 and miR-454-3p) had lower baseline expression in patients with subsequent fibrosis regression. In all, 27 miRNAs differed at week 240 and had higher expression in patients with fibrosis regression (eg miR-199a-3p, miR-423-3p, miR-142-3p, miR-let-7d-5p). Several miRNAs (miR-141-3p, let-7d-5p) that correlated with regression have previously been implicated in the pathophysiology of non-alcoholic steatohepatitis. In cirrhotic patients with chronic HBV infection treated with antiviral therapy, serum miRNAs have differential expression based on fibrosis regression, suggesting potential utility as biomarkers.
Sections du résumé
BACKGROUND AND AIMS
Most patients with cirrhosis induced by chronic HBV infection experience fibrosis regression after long-term antiviral treatment, while some remain cirrhotic. Fibrosis regression is associated with lower odds of developing hepatic decompensation and hepatocellular carcinoma, but mechanisms impacting differential fibrosis regression between individuals are unclear. We asked whether soluble molecules, including serum microRNAs, could serve as biomarkers of fibrosis regression.
METHODS
We analysed cryopreserved sera from clinical trials in which cirrhotic HBV-infected patients (baseline Ishak fibrosis score of 5-6) received 240 weeks of nucleotide analogue treatment. Liver biopsies at week 240 in these trials showed 71/96 patients (74%) had fibrosis regression (Ishak ≤ 4) while 25/96 (26%) remained cirrhotic (Ishak 5-6). We quantified inflammatory markers (CXCL10, soluble CD163) and miRNAs (n = 179) from serum at baseline, week 48 and week 240 of treatment in a sub-cohort of patients with (n = 14) or without (n = 14) fibrosis regression.
RESULTS
CXCL10, sCD163 and miRNAs previously associated with HBV replication and inflammation decreased during treatment but did not differ based on fibrosis regression. Two miRNAs (miR-421 and miR-454-3p) had lower baseline expression in patients with subsequent fibrosis regression. In all, 27 miRNAs differed at week 240 and had higher expression in patients with fibrosis regression (eg miR-199a-3p, miR-423-3p, miR-142-3p, miR-let-7d-5p). Several miRNAs (miR-141-3p, let-7d-5p) that correlated with regression have previously been implicated in the pathophysiology of non-alcoholic steatohepatitis.
CONCLUSIONS
In cirrhotic patients with chronic HBV infection treated with antiviral therapy, serum miRNAs have differential expression based on fibrosis regression, suggesting potential utility as biomarkers.
Identifiants
pubmed: 32301252
doi: 10.1111/liv.14474
pmc: PMC7681260
mid: NIHMS1646553
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1693-1700Subventions
Organisme : NIAID NIH HHS
ID : K08 AI121348
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM130457
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK123704
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Hepatology. 2016 Feb;63(2):388-97
pubmed: 26251317
Clin Chem. 2015 Nov;61(11):1333-42
pubmed: 26408530
Gut Liver. 2017 Nov 15;11(6):860-869
pubmed: 28750488
J Viral Hepat. 2015 Apr;22(4):427-32
pubmed: 25181653
JCI Insight. 2017 Nov 2;2(21):
pubmed: 29093267
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403
pubmed: 29599078
Lancet. 2013 Feb 9;381(9865):468-75
pubmed: 23234725
J Infect Dis. 2017 May 1;215(9):1421-1429
pubmed: 28368488
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):370-377
pubmed: 27956256
Hepatology. 2016 Sep;64(3):732-45
pubmed: 27227815
BMC Genomics. 2014 Jun 14;15:474
pubmed: 24928098
Dis Markers. 2015;2015:893594
pubmed: 25814782
Cell Physiol Biochem. 2017;41(1):310-322
pubmed: 28135713
Hepatology. 2015 Mar;61(3):1066-79
pubmed: 25066777
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):71-72
pubmed: 28053337
Hepatology. 2018 Jun;67(6):2414-2429
pubmed: 29091291
Hepatology. 2018 Jun;67(6):2082-2084
pubmed: 29315674
Clin Gastroenterol Hepatol. 2017 Jul;15(7):1087-1094.e2
pubmed: 28215615
Hepatology. 2018 May;67(5):1695-1709
pubmed: 29194684
Lancet. 2017 Feb 18;389(10070):709-717
pubmed: 28087069
Curr Opin Virol. 2014 Aug;7:1-10
pubmed: 24721496
Biochem Biophys Res Commun. 2016 May 20;474(1):57-63
pubmed: 27107702
Clin Gastroenterol Hepatol. 2013 Mar;11(3):224-31.e1-5
pubmed: 23305825
J Viral Hepat. 2015 Dec;22(12):1079-87
pubmed: 26146764
Inflamm Regen. 2016 Oct 18;36:19
pubmed: 29259692
Hepatology. 2010 Sep;52(3):886-93
pubmed: 20683932